Incidence of nephrotoxicity in HIV patient treated with tenofovir, King Narai Hospital
Keywords:
Nephrotoxicity in HIV patient, TenofovirAbstract
The purpose of this research is to study Incidence of nephrotoxicity and functional change in the kidneys after using tenofovir for 2 years. Furthermore, factor Influencing functional change in the kidneys of HIV patient treated with tenofovir was also studies. This research is retrospective and patient’s follow-up for prospective study of in HIV patient treated with tenofovir. 184 HIV patients were studied. The increasing of serum creatinine (Scr) is ≥ 1.5 times or decreasing of eGFR is > 25% the baseline value of the patient. The research methodology is the recorded data, creating by authors. The data analysis was using statistics, percentage, frequency, average, standard deviation, correlation and multiple regression analysis.
From the results, ratios of male and female patient were similar (1.27/1.0). The mean age of the patients was 41.38 years (19-81 years). The average weight of the patients was 58.12 kg. (40-80 kg.). Period time of the treatment with other antiviral drug was average of 33.95 months (1-120 month). The reason for using other antiviral drug was resulted from lipodystrophy, (68 of patient, 36.95%) and drug resistance of GOVIR S30 (54 of patient, 29.34%), respectively. The kidney function was significantly reduced (P≤ 0.05). Nephrotoxicity was found in 6 patients (3.26%). The median of duration time on nephrotoxicity in HIV patient after treatment with tenofovir was 6 months. From the studying of factors influencing functional change in the kidneys of HIV patient treated with tenofovir, gender, age, Period time of the treatment with other antiviral drug and serum creatinine were affected by the reduction of kidney function. Weight is a factor for deceasing of nephrotoxicity rate (p≤ 0.05). From the efficiency evaluation before and after treatment of tenofovir, viral load drug resistance
From the study, Tenofovir is a good efficiency antiviral drug for HIV patient treatment in King Narai Hospital. The Incidence of nephrotoxicity was found a few patients. However, the monitoring of kidney function it is essential in order for patient safety.
Downloads
References
Hammer SM, Eron JJ, Reiss P, Schooley R.T, Thompson MA, Walmsley S, etal. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. Jama 2008 ; 300(5) : 555-70.
กรมควบคุมโรค. (2561). แนวทางการตรวจรักษาและป้องกันการติดเชื้อเอชไอวีประเทศไทย ปี 2561. พิมพ์ครั้งที่ 1. กรุงเทพฯ: โรงพิมพ์ชุมนุมสหกรณ์การเกษตรแห่งประเทศไทยจำกัด.
Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, comparedwith nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005 ; 40(8) : 1194-8.
Harris M. Yip B, Zalunardo N. Increases in creatinine during therapy with tenefovir DF. In: Program and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis inhibitor treatmemt. Clin Infect Dis 2005 ; 40 : 1194-8.
Zimmermann AE,Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006 ; 42(2) : 283-90.
Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003 ; 36(8) : 1070-3.
Coca S, Perazella MA. Rapid communication : acute renal failure associated withtenofovir : evidence of drug-induced nephrotoxicity. Am J Med Sci 2002 ; 324(6) : 342-4.
Perazella MA. Drug-induced renal failure: update on new medications andunique mechanisms of nephrotoxicity. Am J Med Sci 2003 ; 325(6) : 349-62.
Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005 ; 20(4) : 743-6.
Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005 ; 45(5) : 804-17.
Del Palacio M, Romero S, & Casado J. L. Proximal tubular renal dysfunction or damage in HIV-infected patients. AIDS Rev 2012: 14(3) : 179-187.
Verhelst D, Monge, M, Meynard, J. L, Fouqueray B, Mougenot B, Girard P. M., Rossert J. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002 ; 40(6) : 1331-3.
งานสถิติโรคเอดส์โรงพยาบาลพระนารายณ์มหาราช. สถิติโรคเอดส์ประจำปี พ.ศ.2559-2560 โรงพยาบาลพระนารายณ์มหาราช, 2560.
Perazella M. A. Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney Int 2010 ; 78(11) : 1060-3.
Cassetti I, Madruga Jose Valaez R, Suleiman M A.H, Etzel Arnaldo, Zhong L, Cheng AK, et al. The safty and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antireoviral-naïve HIV-1-1 infected patients. HIV clin Trial 2007 ; 8(3) : 164-72.
Giordano M, Bonfanti P, De Socio GV, Carradori S, Grosso C, Marconi P, et al. Tenofovir renal safty in HIV-infected patients : Results from the SCOLTA Project. Biomedicine & Phamacotherapy 2008 ; 62 : 6-11.
Hall A. M, Hendry B. M, Nitsch D, & Connolly J. O. Tenofovir-associated kidney toxicity in HIV-infected patients : a review of the evidence. Am J Kidney Dis 2011 ; 57(5): 773-780.
Gupta, S. K. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008 ; 22(2) : 99-103.
สุนีย์ ชยางศุ. ผลการทำงานของไตในผู้ป่วยเอดส์ที่ได้รับยาทีโนโฟเวียร์ติดตามเป็นเวลาสองปี. วารสารการแพทย์โรงพยาบาลศรีสะเกษ 2560 ; 32(1) : 1-11.
เกศรินทร์ ชัยศิริ, จุรีรัตน์ บวรวัฒนนุวงศ์, นารัต เกษตรทัต และ ศศิโสภิณ เกียรติบูรณกิจ. อุบัติการณ์ของการเกิดพิษต่อไตในผู้ป่วยติดเชื้อ เอช ไอ วี ที่ใช้ยาทีโนโฟเวียร์ ในโรงพยาบาลชลบุรี. วารสารโรงพยาบาลชลบุรี 2553 ; 35(1) : 1-10.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Singburi Hospital Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The published articles are copyrighted by Singburi Hospital.
The statements appearing in each article in this academic journal are the personal opinions of each author and are not related in any way to Singburi Hospital or other hospital personnel. Each author is solely responsible for all contents of their article. If there are any errors, each author alone will be responsible for their own article.
